Next Generation Sequencing Veteran Joins Biocept, Inc.
SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Jason Poole, Ph.D. has joined the Company as Senior Director, Molecular Assay Development.
Dr. Poole brings extensive molecular diagnostic development experience to Biocept. Previously, Dr. Poole was Director, R&D at Trovagene. He has also worked with EMD Millipore as well as Nanogen, Inc. Dr. Poole has an extensive clinical assay development background, including significant experience in Next Generation Sequencing, quantitative PCR and in-vitro cell analysis.
"I am very pleased to have Jason as part of the Biocept team. He has broad experience in clinical molecular diagnostic development and importantly, has experienced a great deal of success using cell free tumor DNA as a sample target. This experience fits very well with the planned expansion of Biocept's molecular biomarker product offerings using our SelectorTM technology together with Next Generation Sequencing platforms to further personalize cancer treatments and monitor disease progression using ctDNA," said Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer.
"Biocept provides a great opportunity to be part of an organization that is making excellent progress in developing a menu of blood-based tests with the potential to garner as much information about the genomic status of a tumor as an invasive surgical tissue biopsy," Dr. Poole said. "I believe the liquid biopsy will play an increasingly important role in cancer treatment as blood samples are easy to obtain from patients in the physician's office, negating the need for a risky and expensive surgical procedure in the hospital. I am excited to join the Biocept team and help enhance the Company's cutting edge diagnostics in order to improve patient outcomes while reducing testing and treatment costs."
Dr. Poole holds a doctorate in Cancer Genetics from the University of Illinois at Chicago. He was a post-doctoral fellow at the University of California, Irvine, where he developed diagnostic assays for inborn errors of metabolism and other human metabolic diseases.
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-GATM, OncoCEE-BRTM and OncoCEE-LUNGTM test, respectively for gastric, breast and lung cancer and plans to introduce additional CLIA validated tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to medical trends, expansion of offerings and anticipated product introductions, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings, including without limitation our need to grow our business and our operations, our need for capital, and the effects of reimbursement limitations and other health care statutory and regulatory initiatives. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC's website located at www.sec.gov
CONTACT: Investor Contact: The Ruth Group David Burke/Lee Roth (646) 536-7009 / (646) 536-7012 dburke@theruthgroup.com/lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton (646) 536-7023 msollid@theruthgroup.com 
Help employers find you! Check out all the jobs and post your resume.